AVEDRO INC
AVEDRO INC (AVDR): 4 pipeline candidates · ~30 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.7 months
D/E 0.69 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for AVEDRO INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$52.7M
Quarterly Burn
$5.9M
Runway
29.7 mo
Revenue
$11.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| epi-on | Phase 3 |
| hydroxyurea | Approved |
| kxl system + photrexa formulations | Approved |
| leucovorin | Approved |
Frequently asked questions
How many drug candidates are in AVEDRO INC's pipeline?
AVEDRO INC (AVDR) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AVEDRO INC's lead drug candidate?
AVEDRO INC's most advanced tracked candidate is epi-on (Phase 3) for progressive keratoconus.
What is AVEDRO INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AVEDRO INC has approximately 29.7 months of cash runway.
Get the full picture on AVEDRO INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.